Literature DB >> 26793999

The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.

Christine V Möser1, Markus Meissner2, Kathrin Laarmann3, Katrin Olbrich3, Tanya S King-Himmelreich3, Miriam C Wolters3, Gerd Geisslinger4, Ellen Niederberger3.   

Abstract

Inhibitor-kappaB kinase epsilon (IKKε) constitutes a non-canonical I-κB kinase, which amongst others modulates NF-κB activity. IKKε and NF-κB have both been described for their role in cell proliferation and their dysregulation has been associated with tumourigenesis and metastasis in multiple cancer types. Accordingly, overexpression and constitutive activation of NF-κB have also been shown in melanoma, however, the role of IKKε in this cancer type has not been investigated so far. Thus, we determined IKKε expression in malignant melanoma cells and we were able to show a significant overexpression of IKKε in tumour cells in comparison to melanocytes. Inhibition of IKKε either by shRNA or the pharmacological inhibitor amlexanox resulted in reduced cell proliferation associated with a cell cycle block in the G1-phase. Functional analysis indicated that NF-κB, Akt1 and MAPK pathways might be involved in the IKKε-mediated effects. In vivo, we applied a mouse melanoma skin cancer model to assess tumour growth and melanoma-associated pain in IKKε knockout mice as well as C57BL/6 mice after inoculation with IKKε-negative cells. In IKKε knockout mice, tumour growth was not altered as compared to IKKε wild type mice. However, melanoma associated pain was strongly suppressed accompanied by a reduced mRNA expression of a number of pain-relevant genes. In contrast, after inoculation of IKKε-depleted tumour cells, the development of melanoma was almost completely prevented. In conclusion, our data suggest that IKKε in the tumour plays an essential role in tumour initiation and progression while IKKε expression in tumour surrounding tissues contributes to melanoma-associated pain.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amlexanox; IKKε; Melanoma; NF-κB; Pain; Tumour growth

Mesh:

Substances:

Year:  2016        PMID: 26793999     DOI: 10.1016/j.bcp.2015.12.016

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Ceramide synthase 2 deficiency aggravates AOM-DSS-induced colitis in mice: role of colon barrier integrity.

Authors:  Stephanie Oertel; Klaus Scholich; Andreas Weigert; Dominique Thomas; Julia Schmetzer; Sandra Trautmann; Marthe-Susanna Wegner; Heinfried H Radeke; Natalie Filmann; Bernhard Brüne; Gerd Geisslinger; Irmgard Tegeder; Sabine Grösch
Journal:  Cell Mol Life Sci       Date:  2017-04-12       Impact factor: 9.261

Review 2.  Targeting IκappaB kinases for cancer therapy.

Authors:  Nikee Awasthee; Vipin Rai; Srinivas Chava; Palanisamy Nallasamy; Ajaikumar B Kunnumakkara; Anupam Bishayee; Subhash C Chauhan; Kishore B Challagundla; Subash C Gupta
Journal:  Semin Cancer Biol       Date:  2018-02-24       Impact factor: 15.707

3.  The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.

Authors:  Moritz Möller; Julia Wasel; Julia Schmetzer; Ulrike Weiß; Markus Meissner; Susanne Schiffmann; Andreas Weigert; Christine V Möser; Ellen Niederberger
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

4.  IKK Epsilon Deficiency Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice by Inhibiting Inflammation, Oxidative Stress, and Apoptosis.

Authors:  Hao Chai; ZhongHao Tao; YongChao Qi; HaoYu Qi; Wen Chen; YueYue Xu; LeiYang Zhang; HongWei Chen; Xin Chen
Journal:  Oxid Med Cell Longev       Date:  2020-01-22       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.